Evaluation of in vitro and in vivo activity of thiosemicarbazones compounds encapsulated in lipid microemulsions utilizing nanotechnology

• Grant number: 15/02011-5
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Start date until: May 01, 2015
• End date until: November 30, 2015
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Fernando Rogério Pavan
• Grantee: Marcelo Miyata
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil
• Associated research grant: 13/14957-5 - Research potential against tuberculosis of a new class of furoxan compounds and nanostructured compounds of the ruthenium(II) and copper (II), AP.JP

Abstract

Due to increasing of TB cases around the world, the search for new drugs is rising. For viability of a new drug, its time of treatment must be shorter, must be active against resistant strains and/or multidrug resistant strains and must be active against latent strains. Thiosemicarbazones compounds showed previously excellent activity against M. tuberculosis H37Rv. Nanoencapsulation of these compounds inside lipid microemulsions has as purpose to get better results of activity and cytotoxicity in vitro and in vivo. The characterization of thiosemicarbazones compounds non-encapsulated is being performed during the postdoc of Marcelo Miyata student, in the Institute for Tuberculosis Research at University of Illinois at Chicago (UIC) under supervision of Dr. Scott Franzblau. The characterization of these compounds encapsulated aims to compare the results before and after encapsulation, allowing getting similar levels of in vitro activity, increasing the solubility of compounds, improving absorption and activity against M. tuberculosis utilizing mice model. (AU)